Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $50.11 Consensus Target Price from Analysts

Key Points

• Celldex Therapeutics has received a consensus recommendation of "Moderate Buy" from nine brokerages, with an average 1-year target price of $50.11.
• The company's stock recently opened at $20.66, reflecting a market cap of $1.37 billion and a price-to-earnings ratio of -6.86.
• In its latest quarterly earnings report, Celldex reported a loss of ($0.85) EPS, slightly beating analyst expectations, despite a revenue of only $0.73 million versus the anticipated $1.13 million.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $51.75.

CLDX has been the topic of a number of recent analyst reports. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 target price on the stock. UBS Group cut their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a research note on Friday, June 13th. Finally, Morgan Stanley cut their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently modified their holdings of CLDX. Deep Track Capital LP acquired a new stake in shares of Celldex Therapeutics during the fourth quarter worth $38,919,000. Point72 Asset Management L.P. lifted its holdings in Celldex Therapeutics by 50.8% in the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after acquiring an additional 847,264 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after acquiring an additional 676,771 shares during the period. Nuveen LLC acquired a new stake in Celldex Therapeutics in the first quarter valued at $7,789,000. Finally, Segall Bryant & Hamill LLC acquired a new stake in Celldex Therapeutics in the second quarter valued at $7,894,000.

Celldex Therapeutics Trading Up 6.4%

NASDAQ CLDX traded up $1.51 during trading hours on Friday, reaching $25.31. The company had a trading volume of 1,447,387 shares, compared to its average volume of 941,994. The stock has a 50-day moving average of $21.62 and a 200 day moving average of $20.68. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $47.00. The stock has a market capitalization of $1.68 billion, a P/E ratio of -8.44 and a beta of 1.22.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. As a group, sell-side analysts predict that Celldex Therapeutics will post -2.48 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.